Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

被引:69
作者
Mayer-Hamblett, Nicole [1 ,2 ]
Kronmal, Richard A. [3 ]
Gibson, Ronald L. [1 ,2 ]
Rosenfeld, Margaret [1 ,2 ]
Retsch-Bogart, George [4 ]
Treggiari, Miriam M. [5 ]
Burns, Jane L. [1 ,2 ]
Khan, Umer [2 ]
Ramsey, Bonnie W. [1 ,2 ]
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[2] Seattle Childrens Hosp, Seattle, WA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA
[5] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA
关键词
new acquisition; early intervention; eradication; clinical outcome; YOUNG-CHILDREN; COLONIZATION; PREDICTORS; MORTALITY; TOBRAMYCIN; INFECTION; GENOTYPE;
D O I
10.1002/ppul.21525
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Rationale The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown. Objectives: To determine if failure of antibiotic therapy to eradicate Pa and frequency of Pa recurrence are associated with increased exacerbation risk. Methods: The cohort included 282 children with CF who participated in the EPIC trial ages 1-12 with newly acquired Pa, defined as either a first lifetime Pa positive respiratory culture or positive after two years of negative cultures (past isolation of Pa but > 2 years prior to the trial). All received antibiotics to promote initial eradication followed by 15 months of intermittent maintenance antibiotics. Quarterly cultures were used to define initial eradication success and subsequent number of Pa recurrences. A standardized symptombased definition of exacerbation was utilized. Cox proportional hazards models were used to estimate exacerbation risk. Results: Failure to initially eradicate Pa was associated with exacerbation risk (hazard ratio [HR]: 2.49, 95% confidence interval [CI] 1.26, 4.93). In 245/282 with successful initial eradication during the trial, past isolation of Pa > 2 years before the trial was the most significant predictor of exacerbation (HR 1.62, 95% CI 1.12, 2.35). In 37/282 who failed initial eradication, persistent Pa during the maintenance phase (1 or more Pa recurrences after failure to initially eradicate) added even greater exacerbation risk (HR 4.13, 95% CI 1.28, 13.32). Conclusions: Children with CF who fail to eradicate after initial antibiotic treatment are at higher risk of subsequent exacerbation, suggesting clinical benefit to successful early eradication of Pa infection. Pediatr Pulmonol. 2012; 47: 125-134. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:125 / 134
页数:10
相关论文
共 50 条
[41]   Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis [J].
Langan, Katherine M. ;
Kotsimbos, Tom ;
Peleg, Anton Y. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2015, 28 (06) :547-556
[42]   Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis [J].
Waters, Valerie ;
Grimwood, Keith .
JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (03) :292-293
[43]   Antibody Response to Pseudomonas aeruginosa in Children With Cystic Fibrosis [J].
Milagres, Lucimar G. ;
Castro, Tatiana L. A. ;
Garcia, Daniely ;
Cruz, Aline C. ;
Higa, Laurinda ;
Folescu, Tania ;
Marques, Elizabeth A. .
PEDIATRIC PULMONOLOGY, 2009, 44 (04) :392-401
[44]   Early Eradication of Pseudomonas aeruginosa in Patients with Cystic Fibrosis [J].
Stuart, Bridget ;
Lin, Jenny H. ;
Mogayzel, Peter J., Jr. .
PAEDIATRIC RESPIRATORY REVIEWS, 2010, 11 (03) :177-184
[45]   S3 guidelines on pulmonary disease in cystic fibrosis. Module 1: diagnostics and therapy after initial detection of Pseudomonas aeruginosa [J].
Mueller, F. -M. ;
Bend, J. ;
Huttegger, I. ;
Moeller, A. ;
Schwarz, C. ;
Abele-Horn, M. ;
Ballmann, M. ;
Bargon, J. ;
Baumann, I. ;
Bremer, W. ;
Bruns, R. ;
Brunsmann, F. ;
Fischer, R. ;
Geidel, C. ;
Hebestreit, H. ;
Hirche, T. O. ;
Hogardt, M. ;
Illing, S. ;
Koitschev, A. ;
Kohlhaeufl, M. ;
Mahlberg, R. ;
Mainz, J. G. ;
Pfeiffer-Auler, S. ;
Puderbach, M. ;
Riedler, J. ;
Schulte-Hubbert, B. ;
Sedlacek, L. ;
Sitter, H. ;
Smaczny, C. ;
Staab, D. ;
Tuemmler, B. ;
Vonberg, R. -P. ;
Wagner, T. O. F. ;
Zerlik, J. ;
Rietschel, E. .
MONATSSCHRIFT KINDERHEILKUNDE, 2015, 163 (06) :590-599
[46]   Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort [J].
Rosenfeld, Margaret ;
Emerson, Julia ;
McNamara, Sharon ;
Thompson, Valeria ;
Ramsey, Bonnie W. ;
Morgan, Wayne ;
Gibson, Ronald L. .
JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) :446-453
[47]   Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients [J].
Schelstraete, Petra ;
Deschaght, Pieter ;
Van Simaey, Leen ;
Van Daele, Sabine ;
Haerynck, Filomeen ;
Vaneechoutte, Mario ;
De Baets, Frans .
JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (02) :99-103
[48]   Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients [J].
Luo, R-G. ;
Miao, X-Y. ;
Luo, L-L. ;
Mao, B. ;
Yu, F-Y. ;
Xu, J-F. .
CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (05) :601-606
[49]   Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden [J].
Knudsen, Per Kristian ;
Olesen, Hanne V. ;
Hoiby, Niels ;
Johannesson, Marie ;
Karpati, Ferenc ;
Laerum, Birger N. ;
Meyer, Peter ;
Pressler, Tacjana ;
Lindblad, Anders .
JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (02) :135-142
[50]   Effectiveness of a multistep Pseudomonas aeruginosa eradication treatment protocol in children with cystic fibrosis in Brazil [J].
Riquena, Barbara ;
Ferreira da Silva Filho, Luiz Vicente Ribeiro ;
Aversa Nakaie, Cleyde Myriam ;
de Almeida, Marina Buarque ;
Rodrigues, Joaquim Carlos ;
Adde, Fabiola Villac .
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2020, 46 (04) :1-6